Labcorp Holdings Inc. (LH)
Labcorp runs laboratories. One half tests patient samples for doctors, hospitals and patients; the other runs laboratory work for drug companies developing and trialling medicines. During 2025 its nearly 71,000 employees served clients in approximately 100 countries and performed more than 750 million tests, and the company reports that it supported more than 85 percent of the new drugs and therapeutic products approved by the FDA that year. There are two reportable segments: Diagnostics Laboratories, which the company shortens to Dx, and Biopharma Laboratory Services, shortened to BLS.
Compare with another name What $10,000 in Labcorp Holdings became Open in your desk ↗
Latest results
this quarterthe same quarter a year earlierHover a bar for its figure.
this yearthe year beforeHover a bar for its figure.
The years before, in words
Labcorp Holdings (LH) reported revenue of $14.0 billion for fiscal 2025, the year ended 31 December 2025, up 7.2% on the year before. Net income was $876 million and diluted earnings per share $10.46. Revenue was $13.0 billion in fiscal 2024, $12.2 billion in fiscal 2023, $11.9 billion in fiscal 2022 and $13.1 billion in fiscal 2021. Net income in the same years was $746 million, $418 million, $1.3 billion and $2.4 billion. Over the twelve months to 30 September 2026, Labcorp Holdings reported revenue of $14.6 billion and net income of $1.0 billion. Revenue fell 0.0% a year, compounded, over the five years to fiscal 2025. Labcorp Holdings declared $2.88 a share in dividends over the last four quarters and had 81 million shares outstanding at the latest filed count. At 30 September 2026 it carried $5.9 billion of debt and $262 million of cash. At the close of 6 November 2026 the market cap of Labcorp Holdings was $29.8 billion, 30.1 times its earnings over the last twelve months.Ratios
From the filings
ROE11.3%
ROCE10.2%
Operating margin10.3%
Net margin6.9%
FCF margin8.8%
Interest cover6.5x
Debt to equity0.66x
Cash conversion1.81x
Share count, last 12 months-2.2%
Sales CAGR, 3 years5.6%
Profit CAGR, 3 years-11.8%
EPS, TTM$12.19
At the close of 6 November 2026
Price$366.64
Market cap$29.8 billion
Stock P/E30.1x
Price to book3.4x
EV / EBITDA16.0x
Dividend yield0.8%
Market cap / sales2.0x
52-week high$368.11
52-week low$246.64
Price, 1 year48.7%
Price CAGR, 3 years21.0%
Price CAGR, 5 years9.4%
29 ready-made ratios, from FCF yield to net debt to EBITDA, wait on the Formulas page, each with what it tells you. Browse and add them →
Worked from the filed figures; hover a name for the formula.
Read more
The priced ones use the latest price, the last regular-hours trade on IEX. Debt to equity here stands on long-term debt as Labcorp Holdings Inc. files it, with lease liabilities counted separately and never inside it. Nothing here is a valuation or a view.LHgreeksoup.ai
Daily prices to 6 November 2026, adjusted for splits; from 28 September 2026 each day's price is the last regular-hours trade on IEX.
Read more
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. Day by day for the last three years; before that one point a week, carrying the week's last close and its average daily volume, so a volume bar means the same thing across the whole series; the bars sit under the price on their own scale, on the right. The moving averages need consecutive days and are drawn from the daily part. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Before the quarters on file begin, P/E, price to book and market cap to sales stand on each annual report from the day it was filed. Drawn in your browser; the range and overlay you pick are remembered here only.Quarterly results
| Q4 FY2021 * | Q1 FY2022 | Q2 FY2022 † | Q3 FY2022 † | Q4 FY2022 * | Q1 FY2023 † | Q2 FY2023 | Q3 FY2023 | Q4 FY2023 * † | Q1 FY2024 | Q2 FY2024 | Q3 FY2024 | Q4 FY2024 * | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 * | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4,056 | 3,900 | 2,923 | 2,867 | 3,674 | 3,038 | 3,034 | 3,057 | 3,033 | 3,177 | 3,221 | 3,282 | 3,329 | 3,345 | 3,527 | 3,564 | 3,516 | 3,538 | 3,731 | 3,810 |
| Cost of revenue | 2,681 | 2,667 | 1,980 | 1,981 | 2,704 | 2,188 | 2,192 | 2,206 | 2,212 | 2,279 | 2,294 | 2,378 | 2,433 | 2,397 | 2,481 | 2,538 | 2,523 | 2,524 | 2,619 | 2,702 |
| Gross profit | 1,375 | 1,233 | 942 | 886 | 970 | 850 | 842 | 851 | 821 | 897 | 926 | 904 | 896 | 948 | 1,046 | 1,025 | 993 | 1,014 | 1,112 | 1,108 |
| Gross margin | 34% | 32% | 32% | 31% | 26% | 28% | 28% | 28% | 27% | 28% | 29% | 28% | 27% | 28% | 30% | 29% | 28% | 29% | 30% | 29% |
| SG&A | 544 | 464 | 432 | 453 | 536 | 457 | 506 | 526 | 533 | 508 | 558 | 569 | 595 | 546 | 579 | 552 | 539 | 551 | 577 | 611 |
| Operating income | 731 | 688 | 429 | 374 | 90.7 | 330 | 266 | 252 | -123 | 321 | 295 | 254 | 216 | 326 | 394 | 397 | 268 | 381 | 452 | 402 |
| Operating margin | 18% | 18% | 15% | 13% | 2% | 11% | 9% | 8% | -4% | 10% | 9% | 8% | 7% | 10% | 11% | 11% | 8% | 11% | 12% | 11% |
| Interest expense | 43.1 | 42.2 | 42.3 | 46.3 | 49.3 | 50.7 | 49.8 | 50.3 | 48.8 | 46.9 | 47.6 | 50.4 | 63.4 | 56.0 | 57.1 | 56.0 | 55.0 | 55.1 | 61.1 | 59.1 |
| Net income | 553 | 492 | 359 | 353 | 76.1 | 213 | 189 | 183 | -167 | 228 | 205 | 169 | 143 | 213 | 238 | 261 | 165 | 278 | 299 | 263 |
| Net margin | 14% | 13% | 12% | 12% | 2% | 7% | 6% | 6% | -6% | 7% | 6% | 5% | 4% | 6% | 7% | 7% | 5% | 8% | 8% | 7% |
| Diluted EPS | $5.76 | $5.23 | $3.87 | $3.90 | $0.86 | $2.39 | $2.12 | $2.11 | -$1.95 | $2.69 | $2.43 | $2.00 | $1.70 | $2.52 | $2.84 | $3.12 | $1.98 | $3.35 | $3.64 | $3.22 |
| Operating cash flow | 698 | 356 | 572 | 374 | 654 | 121 | 351 | 276 | 580 | -29.8 | 561 | 277 | 777 | 18.5 | 621 | 387 | 614 | 192 | 446 | 564 |
| Capital expenditure | 150 | 117 | 143 | 104 | 118 | 93.9 | 87.6 | 105 | 167 | 134 | 128 | 116 | 112 | 126 | 77.9 | 107 | 124 | 121 | 132 | 152 |
| Free cash flow | 548 | 239 | 429 | 270 | 536 | 27.3 | 264 | 171 | 412 | -164 | 433 | 162 | 665 | -108 | 543 | 280 | 490 | 70.5 | 314 | 412 |
| Buybacks | 1,000 | 0.0 | 400 | 800 | -100 | n/a | n/a | 1,009 | n/a | n/a | n/a | 75.0 | n/a | 0.0 | 200 | 25.0 | 225 | 98.0 | 354 | 0.0 |
| Dividends paid | 0.0 | 0.0 | 66.7 | 64.9 | 63.6 | 64.4 | 64.6 | 63.9 | 61.1 | 62.1 | 60.4 | 60.5 | 60.1 | 61.6 | 59.9 | 59.9 | 59.3 | 61.2 | 58.7 | 58.2 |
| Shares outstanding | 98m | 96m | 91m | 90m | 88m | 89m | 89m | 85m | 84m | 84m | 84m | 84m | 83m | 84m | 83m | 83m | 82m | 82m | 81m | 81m |
| Filing | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q |
Each quarter as filed, linked to its filing.
Read more
* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.Income statement (profit and loss)
Play it forward: change any box and its column follows; every box opens at the company's own record, shown under the row's name, and says when you set it outside every year in the table.
Read more
Each column runs from the last twelve months as filed to the year chosen in its heading, at a yearly rate. Sales growth starts at the company's own five-year rate and eases a third of the way each year toward the median of the 45 peers in Healthcare (13.2% a year), because a rate far from the rest rarely lasts. Before you open a year, the strip reads today's price backwards: the yearly sales growth that brings EPS, at the company's own margins, tax and share count, to today's price at the median P/E of the 33 peers in Healthcare (25.0). Low, middle, high opens three columns for one year: the low and high cases take the company's own weaker and stronger years in the table (the lower and upper quarter of its yearly sales growth and operating margin) and the lower and higher of today's P/E and its peers'; the middle is the boxes as they open. Net income keeps the share that went to minority holders; EPS is net income over the diluted shares, on the same basis as the EPS in the table. The price is that year's EPS at the P/E you set, and the yearly return runs from today's price to the year's end. These are your assumptions and your arithmetic, not an estimate of ours. The link carries your columns, so you can send the forecast to someone.| FY2007 | FY2008 | FY2009 † | FY2010 † | FY2011 † | FY2012 † | FY2013 | FY2014 | FY2015 † | FY2016 † | FY2017 † | FY2018 † | FY2019 † | FY2020 † | FY2021 † | FY2022 † | FY2023 | FY2024 † | FY2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4,068 | 4,505 | 4,695 | 5,004 | 5,542 | 5,671 | 5,808 | 6,012 | 8,680 | 9,553 | 10,308 | 11,333 | 11,555 | 13,978 | 13,136 | 11,864 | 12,162 | 13,009 | 13,952 | 14,594 |
| Cost of revenue | 2,377 | 2,631 | 2,724 | 2,906 | 3,268 | 3,422 | 3,585 | 3,808 | 5,777 | 6,699 | 7,216 | 8,157 | 8,302 | 9,026 | 8,144 | 8,155 | 8,797 | 9,384 | 9,939 | 10,367 |
| Gross profit | 1,691 | 1,874 | 1,971 | 2,098 | 2,275 | 2,250 | 2,223 | 2,203 | 2,903 | 2,854 | 3,092 | 3,176 | 3,252 | 4,953 | 4,992 | 3,709 | 3,365 | 3,624 | 4,012 | 4,227 |
| Gross margin | 41.6% | 41.6% | 42.0% | 41.9% | 41.0% | 39.7% | 38.3% | 36.6% | 33.4% | 29.9% | 30.0% | 28.0% | 28.1% | 35.4% | 38.0% | 31.3% | 27.7% | 27.9% | 28.8% | 29.0% |
| Selling, general and administrative | 809 | 935 | 959 | 1,034 | 1,160 | 1,115 | 1,129 | 1,198 | 1,628 | 1,346 | 1,499 | 1,571 | 1,624 | 1,729 | 1,690 | 1,763 | 2,021 | 2,230 | 2,216 | 2,278 |
| Operating income | 777 | 843 | 936 | 979 | 948 | 1,024 | 991 | 910 | 997 | 1,271 | 1,305 | 1,326 | 1,330 | 2,445 | 3,049 | 1,436 | 726 | 1,087 | 1,385 | 1,502 |
| Operating margin | 19.1% | 18.7% | 19.9% | 19.6% | 17.1% | 18.0% | 17.1% | 15.1% | 11.5% | 13.3% | 12.7% | 11.7% | 11.5% | 17.5% | 23.2% | 12.1% | 6.0% | 8.4% | 9.9% | 10.3% |
| Interest expense | -56.6 | -72.0 | 62.9 | 70.0 | 87.5 | 94.5 | 96.5 | 110 | 275 | 219 | 235 | 244 | 241 | 207 | 212 | 180 | 200 | 208 | 224 | 230 |
| Income tax | 326 | 308 | 329 | 344 | 333 | 359 | 340 | 314 | 287 | 361 | -155 | 384 | 280 | 662 | 690 | 234 | 188 | 212 | 230 | 220 |
| Net income | 477 | 464 | 543 | 558 | 520 | 583 | 574 | 511 | 437 | 712 | 1,227 | 884 | 824 | 1,556 | 2,377 | 1,279 | 418 | 746 | 876 | 1,004 |
| Net margin | 11.7% | 10.3% | 11.6% | 11.2% | 9.4% | 10.3% | 9.9% | 8.5% | 5.0% | 7.5% | 11.9% | 7.8% | 7.1% | 11.1% | 18.1% | 10.8% | 3.4% | 5.7% | 6.3% | 6.9% |
| Diluted EPS | $3.93 | $4.16 | $4.98 | $5.29 | $5.11 | $5.99 | $6.25 | $5.91 | $4.34 | $6.82 | $11.81 | $8.61 | $8.35 | $15.88 | $24.39 | $13.97 | $4.77 | $8.84 | $10.46 | $12.19 |
| Filing | 10-K | 10-K | 10-K | 10-K/A | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
From each year's 10-K, linked; TTM is the last four quarters.
Read more
Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. † The year as the company last restated it in a later filing; rest on a figure for the one first filed. EPS is as filed.Revenue by segment FY2010 to FY2025, 1 year left out
| FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | Share of the parts, latest year | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnostics | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 7,000 | 9,253 | 10,364 | 9,204 | 9,415 | 10,144 | 10,876 | 77.8% |
| Biopharma Laboratory Services | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 2,697 | 2,774 | 2,923 | 3,098 | 22.2% |
| Covance Drug Development | n/a | n/a | n/a | n/a | n/a | 3,246 | 3,452 | 4,313 | 4,578 | 4,878 | 2,861 | n/a | n/a | n/a | n/a | n/a |
| Genomic and Esoteric Testing | 1,728 | 2,089 | 2,090 | 2,020 | 174 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| LabCorp Diagnostics | n/a | n/a | n/a | n/a | n/a | 6,308 | 6,858 | 7,031 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Ontario, Canada | 280 | 309 | 335 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Segments | n/a | n/a | n/a | 343 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Routine Testing | 2,995 | 3,144 | 3,247 | 3,445 | 5,838 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Diagnostics FY2019 to FY2025Biopharma Laboratory Services FY2022 to FY2025Covance Drug Development FY2016 to FY2021LabCorp Diagnostics FY2016 to FY2018Routine Testing FY2010 to FY2014Genomic and Esoteric Testing FY2010 to FY2014Other Segments FY2013Ontario, Canada FY2010 to FY2012
$ billion; hover a block for its figure and share; a part named with years is one the company split its revenue into only then
From the company's 10-Ks, in its own words (latest 10-K).
Read more
Each year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in.Profit by segment FY2016 to FY2025
The operating profit each segment reports. Costs Labcorp Holdings does not charge to a segment are left out, so the segments can add up to more than the company's own operating profit.
| FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | Margin FY2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnostics | n/a | n/a | n/a | 1,086 | 2,801 | 3,206 | 2,026 | 1,591 | 1,606 | 1,780 | 16.4% |
| Biopharma Laboratory Services | n/a | n/a | n/a | n/a | n/a | n/a | 389 | 396 | 459 | 498 | 16.1% |
| Covance Drug Development | 236 | 145 | 304 | 412 | 722 | 501 | n/a | n/a | n/a | n/a | n/a |
| LabCorp Diagnostics | 1,182 | 1,301 | 1,167 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Diagnostics FY2019 to FY2025LabCorp Diagnostics FY2016 to FY2018Biopharma Laboratory Services FY2022 to FY2025Covance Drug Development FY2016 to FY2021
$ million; the figure over a bar is all the segments together. Hover a block for its profit, sales and margin.
FY2025Share of salesShare of profit
Diagnostics78%78%
Biopharma Laboratory Services22%22%
Each column adds to 100%. A segment with a bigger share of the profit than of the sales makes more on each dollar it sells.
From the company's 10-Ks, in its own words (latest 10-K).
Read more
Each year's figures come from the most recent 10-K that includes that year. A year is shown only where every segment with sales that year has an operating profit figure. A margin is a segment's operating profit over its own sales.First forecast against the result
Labcorp Holdings's adjusted EPS landed at or above the top of the range in 1, inside it in 3 and under it in 1 of the 5 years shown (FY2016 to FY2020).
- At or above the top of the range
- Inside the range
- Under the range
Each bar is the year's result against the top of its first forecast range, in per cent of the top. Hover a bar for the figures.
| Fiscal year | First forecast adjusted EPS | Result |
|---|---|---|
| FY2016 | $8.45 to $8.85 | $8.83 |
| FY2017 | $9.35 to $9.75 | $9.60 |
| FY2018 | $11.30 to $11.70 | $11.02 |
| FY2019 | $11.00 to $11.40 | $11.32 |
| FY2020 | $11.75 to $12.15 | $23.94 |
- First forecast
- The full-year range the company gave with its fourth-quarter results for the year before, before any later change to it.
- Result
- The figure the company reported for that year with its next fourth-quarter results.
- Adjusted EPS
- The company's own measure, which leaves out items it names, so it differs from the EPS in the tables above.
- Years left out
- Where the forecast or the result could not be read with confidence. Each figure in the table links to the results release it comes from.
Cash flow
Follow the cash: free cash flow, which is operating cash flow less capital expenditure and share-based pay, for five years and after, in today's money.
Read more
The figure a share at the top is what a discounted cash flow calls intrinsic value, worked out on your assumptions. Everything after year five is one sum: the sixth year's cash, growing at the long-run rate every year after, added up and brought back to today's money. Each year runs from the last twelve months as filed. Sales growth opens where Play it forward does: the company's own five-year rate, easing a third of the way each year toward the median of the 45 peers in Healthcare (13.2% a year); change a year and the years after it follow. Operating cash flow, capital expenditure and share-based pay open at the company's own median share of sales over its last five years, shown under each row. Share-based pay is taken off because operating cash flow adds back the shares paid to staff as if they cost nothing; set it to 0 to leave it in. Capital spending counts every capital line the company files in its cash flow, such as equipment it leases to customers, software, wells or property it develops, named under the row, while the Capital expenditure row in the table below stays the one line as filed; buying a business, securities or a finished property is not counted. The discount rate opens at 10%, about what US stocks have returned a year over the long run, so it is the return you give up by holding this company instead of the market; the growth after year five opens at 3%, a little under the US economy's long-run growth in dollars, because no company outgrows it for ever. Net debt is the debt and short-term borrowings less the cash on the latest balance sheet that shows the debt; the figure per share divides what is left by the diluted share count. These are your assumptions and your arithmetic, not an estimate of ours. The link carries them, so you can send them to someone.| FY2007 | FY2008 | FY2009 † | FY2010 † | FY2011 † | FY2012 † | FY2013 | FY2014 | FY2015 † | FY2016 † | FY2017 † | FY2018 † | FY2019 † | FY2020 † | FY2021 † | FY2022 † | FY2023 | FY2024 † | FY2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 710 | 781 | 862 | 884 | 856 | 841 | 819 | 739 | 982 | 1,197 | 1,498 | 1,305 | 1,445 | 2,135 | 3,110 | 1,956 | 1,328 | 1,586 | 1,640 | 1,815 |
| Capital expenditure | 143 | 157 | 115 | 126 | 146 | 174 | 202 | 204 | 256 | 279 | 313 | 380 | 400 | 382 | 422 | 429 | 454 | 490 | 434 | 528 |
| Free cash flow | 567 | 624 | 748 | 758 | 710 | 668 | 616 | 536 | 727 | 918 | 1,185 | 926 | 1,044 | 1,754 | 2,688 | 1,527 | 874 | 1,096 | 1,206 | 1,287 |
| Free cash flow margin | 13.9% | 13.9% | 15.9% | 15.1% | 12.8% | 11.8% | 10.6% | 8.9% | 8.4% | 9.6% | 11.5% | 8.2% | 9.0% | 12.5% | 20.5% | 12.9% | 7.2% | 8.4% | 8.6% | 8.8% |
| Cash from investing | -342 | -396 | -334 | -1,318 | -280 | -534 | -360 | -350 | -3,995 | -796 | -2,229 | 207 | -1,283 | -643 | -885 | -1,652 | -1,172 | -1,367 | -1,194 | -1,512 |
| Cash from financing | -364 | -218 | -601 | 515 | -645 | -0.8 | -518 | -201 | 3,185 | -671 | 593 | -1,390 | -253 | -517 | -2,066 | -1,322 | -59.3 | 780 | -1,457 | -640 |
| Depreciation and amortisation | 163 | 180 | 195 | 204 | 231 | 230 | 230 | 246 | 458 | 499 | 533 | 552 | 577 | 625 | 577 | 537 | 577 | 644 | 681 | 708 |
| Share-based compensation | 35.4 | 36.2 | 36.4 | 40.0 | 48.9 | 40.7 | 37.3 | 45.7 | 102 | 110 | 110 | 91.6 | 107 | 112 | 133 | 117 | 129 | 117 | 126 | 127 |
| Buybacks | 921 | 334 | 273 | 338 | 644 | 516 | 1,016 | 269 | 0.0 | 43.9 | 338 | 700 | 450 | 100 | 1,668 | 1,100 | 1,000 | 250 | 450 | 677 |
| Dividends paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 0.0 | 0.0 | 195 | 254 | 243 | 241 | 237 |
| Dividend per share | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | $2.16 | $2.88 | $2.88 | $2.88 | n/a |
| Diluted shares, weighted | n/a | 112m | 109m | 105m | 102m | 97m | 92m | 86m | 101m | 104m | 104m | 103m | 99m | 98m | 98m | 92m | 88m | 84m | 84m | 82m |
| Shares outstanding at period end | n/a | 108m | 105m | 102m | 98m | 94m | 86m | 85m | 101m | 103m | 102m | 99m | 97m | 98m | 98m | 88m | 84m | 83m | 82m | 81m |
| Filing | 10-K | 10-K | 10-K | 10-K/A | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
Cash paid in the year, from the cash flow statement.
Read more
The dividend per share is as declared. Diluted shares are the weighted average for the year; a falling count is the buybacks net of issuance. TTM sums the last four quarters; the share counts are the latest quarter's.Balance sheet
| FY2007 | FY2008 | FY2009 † | FY2010 † | FY2011 † | FY2012 † | FY2013 | FY2014 | FY2015 † | FY2016 † | FY2017 † | FY2018 † | FY2019 † | FY2020 † | FY2021 † | FY2022 † | FY2023 | FY2024 † | FY2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Funded by | ||||||||||||||||||||
| Shareholders' equity | 1,725 | 1,688 | 2,106 | 2,466 | 2,504 | 4,945 | 2,491 | 2,820 | 4,944 | 5,518 | 6,804 | 7,048 | 7,644 | 9,437 | 10,273 | 10,097 | 7,875 | 8,052 | 8,620 | 8,848 |
| Non-controlling interest | n/a | 121 | 0.0 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Debt | n/a | 1,600 | 977 | 1,827 | 2,221 | 2,655 | 2,986 | 3,030 | 6,356 | 5,850 | 6,762 | 6,001 | 6,205 | 5,796 | 5,416 | 5,340 | 5,054 | 6,332 | 5,585 | 5,852 |
| Operating lease liabilities | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 0.0 | 597 | 678 | 642 | 653 | 649 | 676 | 683 | 675 |
| Finance lease liabilities | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 51.0 | 91.1 | 84.4 | 84.6 | 83.6 | 78.6 | 74.3 | 63.0 | 61.1 |
| Other liabilities | n/a | 1,259 | 1,754 | 1,895 | 1,387 | n/a | 1,489 | 1,452 | 2,804 | 2,879 | 3,107 | 3,085 | 3,510 | 4,077 | 3,968 | 3,982 | 3,068 | 3,245 | 3,443 | 3,489 |
| Total liabilities and equity | n/a | 4,670 | 4,838 | 6,188 | 6,112 | 6,795 | 6,966 | 7,302 | 14,105 | 14,247 | 16,673 | 16,185 | 18,046 | 20,072 | 20,385 | 20,155 | 16,725 | 18,379 | 18,393 | 18,925 |
| Owned | ||||||||||||||||||||
| Fixed assets | n/a | 496 | 501 | 587 | 578 | 631 | 707 | 786 | 1,747 | 1,719 | 1,707 | 1,740 | 2,637 | 2,730 | 2,815 | 2,794 | 2,912 | 3,045 | 3,082 | 3,143 |
| Goodwill | n/a | 1,772 | 1,897 | 2,601 | 2,682 | 2,902 | 3,023 | 3,099 | 6,202 | 6,424 | 7,401 | 7,360 | 7,865 | 7,752 | 5,891 | 6,124 | 6,142 | 6,370 | 6,790 | 7,177 |
| Intangible assets | n/a | 1,223 | 1,342 | 1,674 | 1,621 | 1,668 | 1,572 | 1,476 | 3,324 | 3,400 | 4,166 | 3,911 | 4,034 | 3,961 | 3,736 | 3,124 | 3,342 | 3,489 | 3,596 | 3,717 |
| Cash and equivalents | 56.4 | 220 | 148 | 159 | 159 | 404 | 404 | 580 | 716 | 434 | 317 | 427 | 338 | 1,321 | 1,473 | 321 | 537 | 1,519 | 532 | 262 |
| Receivables | n/a | 632 | 574 | 656 | 700 | 718 | 785 | 816 | 1,218 | 1,329 | 1,531 | 1,468 | 1,544 | 2,480 | 2,262 | 1,786 | 1,913 | 1,944 | 2,104 | 2,413 |
| Inventory | n/a | 91.0 | 90.0 | 103 | 111 | 121 | 136 | 140 | 191 | 205 | 228 | 237 | 245 | 423 | 401 | 471 | 475 | 493 | 535 | 538 |
| Other assets | n/a | 236 | 285 | 407 | 261 | 351 | 338 | 405 | 706 | 736 | 1,324 | 1,042 | 1,384 | 1,406 | 3,808 | 5,537 | 1,404 | 1,519 | 1,755 | 1,675 |
| Total assets | n/a | 4,670 | 4,838 | 6,188 | 6,112 | 6,795 | 6,966 | 7,302 | 14,105 | 14,247 | 16,673 | 16,185 | 18,046 | 20,072 | 20,385 | 20,155 | 16,725 | 18,379 | 18,393 | 18,925 |
| Filing | 10-K | 10-K | 10-K | 10-K/A | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
At the fiscal year end; the TTM column is the latest quarter end.
Read more
Both totals are the company's own. Other liabilities is the filed total less the rows above it: payables, deferred revenue, taxes, borrowings the rows above do not carry and the rest; other assets is the same on the other side. Investments add the current and non-current lines as filed. Debt is the company's own stated total where it files one, otherwise its long-term debt with the current maturities, never parts added together. A row is left blank in a year where the lines shown overlap and the remainder would fall below nil.Compounded growth
| 10 years | 5 years | 3 years | TTM | |
|---|---|---|---|---|
| Sales growth, compounded | 4.9% | -0.0% | 5.6% | 6.0% |
| Profit growth, compounded | 7.2% | -10.8% | -11.8% | 17.4% |
| Return on equity, average | 13.1% | 12.1% | 8.2% | 10.2% |
Yearly growth, compounded; TTM is the last four quarters against the four before.
Read more
Return on equity is net income over shareholders' equity at each year end, averaged over the window (the TTM column is the latest year alone); equity is the parent's shareholders' equity as tagged in the 10-K. Arithmetic on filed numbers, nothing forecast.Questions
What was Labcorp Holdings' revenue in fiscal 2025?
Labcorp Holdings (LH) reported revenue of $14.0 billion for fiscal 2025, the year ended 31 December 2025, up 7.2% on the year before.
How much did Labcorp Holdings earn in fiscal 2025?
Net income was $876 million for fiscal 2025, and diluted earnings per share $10.46.
What is Labcorp Holdings' P/E ratio?
At the close of 6 November 2026, Labcorp Holdings traded at 30.1 times its earnings over the twelve months to 30 September 2026.
What is Labcorp Holdings' market cap?
The market cap of Labcorp Holdings was $29.8 billion at the close of 6 November 2026.
Does Labcorp Holdings pay a dividend?
Yes. Labcorp Holdings declared $2.88 a share in dividends over the four quarters to 30 September 2026.
Peers: Healthcare
| Company | Market cap | P/E | ROE | Op. margin | Sales growth TTM | Debt to equity | Div. yield |
|---|---|---|---|---|---|---|---|
| Natera, Inc. NTRA | $44.9 billion | n/a | -8.8% | -9.0% | 37.4% | 0.04 | n/a |
| Labcorp Holdings Inc. LH | $29.8 billion | 30.08 | 11.3% | 10.3% | 6.0% | 0.66 | 0.8% |
| Quest Diagnostics Inc. DGX | $28.1 billion | 25.46 | 14.8% | 14.6% | 9.1% | 0.73 | 1.3% |
| Guardant Health, Inc. GH | $20.4 billion | n/a | n/a | -39.4% | 41.7% | n/a | n/a |
| Caris Life Sciences, Inc. CAI | $7.2 billion | 76.45 | 15.0% | 13.4% | n/a | 0.61 | n/a |
| RadNet, Inc. RDNT | $6.0 billion | n/a | -1.9% | 3.1% | 18.9% | 1.22 | n/a |
| BillionToOne, Inc. BLLN | $5.4 billion | 104.29 | 8.7% | 10.2% | n/a | 0.16 | n/a |
| Grail, Inc. GRAL | $5.4 billion | n/a | -16.6% | -347.3% | 17.5% | 0.00 | n/a |
| CareDx, Inc. CDNA | $4.1 billion | 32.86 | 27.5% | 23.4% | 38.9% | 0.00 | n/a |
| Fortrea Holdings Inc. FTRE | $2.1 billion | n/a | -12.9% | 0.5% | -3.4% | 1.98 | n/a |
| Veracyte, Inc. VCYT | $1.9 billion | 15.56 | 8.9% | 17.1% | 17.5% | 0.00 | n/a |
| Personalis, Inc. PSNL | $1.7 billion | n/a | -56.1% | -156.7% | 16.9% | n/a | n/a |
All 59 in Healthcare
| Company | Market cap | P/E | ROE | Op. margin | Sales growth TTM | Debt to equity | Div. yield |
|---|---|---|---|---|---|---|---|
| HCA Healthcare, Inc. HCA | $104.4 billion | 16.40 | n/a | 12.5% | 5.8% | n/a | 0.6% |
| Natera, Inc. NTRA | $44.9 billion | n/a | -8.8% | -9.0% | 37.4% | 0.04 | n/a |
| Labcorp Holdings Inc. LH | $29.8 billion | 30.08 | 11.3% | 10.3% | 6.0% | 0.66 | 0.8% |
| Quest Diagnostics Inc. DGX | $28.1 billion | 25.46 | 14.8% | 14.6% | 9.1% | 0.73 | 1.3% |
| Tenet Healthcare Corp. THC | $22.6 billion | 8.22 | 53.3% | 24.4% | 6.2% | 2.43 | n/a |
| Guardant Health, Inc. GH | $20.4 billion | n/a | n/a | -39.4% | 41.7% | n/a | n/a |
| Encompass Health Corp. EHC | $13.5 billion | 21.49 | 24.0% | 18.3% | 9.4% | 0.97 | 0.6% |
| BrightSpring Health Services, Inc. BTSG | $13.4 billion | 36.31 | 18.8% | 3.4% | 22.9% | 1.00 | n/a |
| Davita Inc. DVA | $12.1 billion | 14.09 | n/a | 15.0% | 6.4% | n/a | n/a |
| Universal Health Services Inc. UHS | $11.3 billion | 8.18 | 19.2% | 10.8% | 8.0% | 0.75 | 0.4% |
| Ensign Group, Inc. ENSG | $10.6 billion | 26.96 | 15.6% | 9.0% | 17.5% | 0.08 | 0.1% |
| Pacs Group, Inc. PACS | $7.9 billion | 28.81 | 22.9% | 7.4% | 12.4% | 0.22 | n/a |
| Caris Life Sciences, Inc. CAI | $7.2 billion | 76.45 | 15.0% | 13.4% | n/a | 0.61 | n/a |
| Chemed Corp. CHE | $6.9 billion | 25.27 | 32.8% | 13.9% | 5.2% | 0.27 | 0.5% |
| Hims & Hers Health, Inc. HIMS | $6.1 billion | n/a | -43.8% | -6.0% | 28.0% | 4.21 | n/a |
| RadNet, Inc. RDNT | $6.0 billion | n/a | -1.9% | 3.1% | 18.9% | 1.22 | n/a |
| BillionToOne, Inc. BLLN | $5.4 billion | 104.29 | 8.7% | 10.2% | n/a | 0.16 | n/a |
| Grail, Inc. GRAL | $5.4 billion | n/a | -16.6% | -347.3% | 17.5% | 0.00 | n/a |
| Concentra Group Holdings Parent, Inc. CON | $5.3 billion | 24.96 | 42.7% | 16.9% | 11.8% | 3.00 | 0.6% |
| LifeStance Health Group, Inc. LFST | $5.2 billion | 72.47 | 4.8% | 6.2% | 22.6% | 0.18 | n/a |
| Option Care Health, Inc. OPCH | $4.7 billion | 22.77 | 16.2% | 5.9% | 4.0% | 0.87 | n/a |
| Sotera Health Co. SHC | $4.6 billion | 26.68 | 23.7% | n/a | 6.9% | 2.91 | n/a |
| CareDx, Inc. CDNA | $4.1 billion | 32.86 | 27.5% | 23.4% | 38.9% | 0.00 | n/a |
| Acadia Healthcare Company, Inc. ACHC | $3.4 billion | n/a | -55.8% | -31.7% | 4.5% | 1.16 | n/a |
| National Healthcare Corp. NHC | $3.3 billion | 28.76 | 10.2% | 9.8% | 5.6% | 0.45 | 1.3% |
| Privia Health Group, Inc. PRVA | $3.1 billion | 93.92 | 4.3% | 2.1% | 19.2% | 0.00 | n/a |
| Surgery Partners, Inc. SGRY | $3.0 billion | n/a | -5.3% | 11.4% | 4.0% | 2.25 | n/a |
| Aveanna Healthcare Holdings, Inc. AVAH | $2.9 billion | 10.76 | 95.6% | 10.5% | 19.5% | 4.52 | n/a |
| Progyny, Inc. PGNY | $2.6 billion | 31.96 | 22.0% | 9.4% | 5.5% | 0.00 | n/a |
| Pediatrix Medical Group, Inc. MD | $2.4 billion | 17.00 | 17.7% | 10.9% | 1.9% | 0.68 | n/a |
| Ardent Health, Inc. ARDT | $2.4 billion | 16.79 | 10.5% | 4.5% | 2.0% | 0.79 | n/a |
| Addus HomeCare Corp. ADUS | $2.3 billion | 20.70 | 9.4% | 10.3% | 11.5% | 0.02 | n/a |
| Brookdale Senior Living Inc. BKD | $2.2 billion | n/a | n/a | 6.8% | -8.4% | n/a | n/a |
| Fortrea Holdings Inc. FTRE | $2.1 billion | n/a | -12.9% | 0.5% | -3.4% | 1.98 | n/a |
| Veracyte, Inc. VCYT | $1.9 billion | 15.56 | 8.9% | 17.1% | 17.5% | 0.00 | n/a |
| agilon health, Inc. AGL | $1.9 billion | 20.59 | -31.0% | -2.6% | 2.0% | 0.11 | n/a |
| GeneDx Holdings Corp. WGS | $1.9 billion | n/a | -43.5% | -20.3% | 25.4% | 0.41 | n/a |
| Personalis, Inc. PSNL | $1.7 billion | n/a | -56.1% | -156.7% | 16.9% | n/a | n/a |
| Healthcare Services Group Inc. HCSG | $1.6 billion | 16.29 | 19.7% | n/a | 4.0% | 0.00 | n/a |
| Teladoc Health, Inc. TDOC | $1.6 billion | n/a | -12.0% | -6.6% | -2.4% | 0.77 | n/a |
| Sonida Senior Living, Inc. SNDA | $1.6 billion | n/a | -14.8% | -11.8% | 70.0% | 1.88 | n/a |
| U S Physical Therapy Inc. USPH | $1.5 billion | n/a | 7.0% | 9.1% | 10.4% | 0.57 | 1.8% |
| Lumexa Imaging Holdings, Inc. LMRI | $1.3 billion | n/a | n/a | n/a | n/a | 1.36 | n/a |
| Pennant Group, Inc. PNTG | $1.3 billion | 36.73 | 8.5% | 5.8% | 38.7% | 0.47 | n/a |
| InnovAge Holding Corp. INNV | $1.2 billion | 149.67 | 3.5% | 1.4% | 15.1% | 0.19 | n/a |
| Castle Biosciences Inc. CSTL | $1,000 million | n/a | -4.8% | -7.4% | 9.8% | 0.02 | 0.0% |
| AdaptHealth Corp. AHCO | $999 million | n/a | -33.2% | -11.5% | -3.2% | 1.54 | n/a |
| Omada Health, Inc. OMDA | $936 million | 71.90 | 5.1% | 2.1% | n/a | 0.00 | n/a |
| Starling Oncology, Inc. STLN | $682 million | n/a | n/a | -3.4% | 34.6% | n/a | n/a |
| Fulgent Genetics, Inc. FLGT | $660 million | n/a | -9.2% | -39.2% | 4.7% | 0.00 | n/a |
| SBC Medical Group Holdings Inc. SBC | $522 million | 10.83 | 18.6% | 37.3% | -6.9% | 0.14 | n/a |
| Viemed Healthcare, Inc. VMD | $348 million | 24.05 | 10.4% | 7.8% | 21.8% | 0.03 | n/a |
| Community Health Systems Inc. CYH | $311 million | 8.48 | n/a | 10.9% | -7.8% | n/a | n/a |
| Exagen Inc. XGN | $141 million | n/a | -154.9% | -18.6% | 20.8% | 1.87 | n/a |
| LifeMD, Inc. LFMD | $113 million | n/a | n/a | n/a | n/a | 0.00 | n/a |
| Sera Prognostics, Inc. SERA | $112 million | n/a | -63.8% | -38,755.2% | 1.1% | 0.00 | n/a |
| Park Dental Partners, Inc. PARK | $94 million | n/a | n/a | n/a | n/a | 0.37 | n/a |
| Biodesix Inc. BDSX | $94 million | n/a | -312.1% | -18.7% | 31.2% | 5.76 | n/a |
| Airsculpt Technologies, Inc. AIRS | $39 million | n/a | -8.9% | -4.7% | -6.3% | 0.35 | n/a |
17 companies share its SEC industry code (Services-Medical Laboratories); the rest are the names nearest in size in its wider industry, Healthcare, one of the Fama-French 48 industries, a published grouping of SEC industry codes.
Read more
By market capitalisation; a click on a heading sorts by it, largest first, and a second click turns it round. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close; a name marked * is a foreign company that files once a year, on its latest fiscal year.The public record on LH
| Dividends | $2.88 a share over the four quarters to 30 September 2026, a 0.79% yield |
| Filings | 35 in twelve months: 27 current reports (8-K), about 18 regulation FD disclosure; 5 officer or director change; 4 results of operations; 2 material agreement; 2 new financial obligation |
| Planned insider sales | 21 Form 144 notices in twelve months, $16.1 million; latest 4 November 2026 |
| Options tape | put/call 0.77 by open interest at the 6 November 2026 close; the straddle prices a 4.4% move to 20 November 2026 |
| 13F holders | 1,051 funds reported a position for the quarter to 30 June 2026; largest BlackRock, Inc. |
| Insider trading | 22 sales and 0 purchases on Form 4 in twelve months |
| Congress | 4 House trades disclosed in six months |
| Short interest | 2.6 million shares short, 4.22 days to cover at 15 October 2026 |
| Documents | the 10-K, the 10-Qs, the proxy and 4 earnings press releases, each linked |
Filings
| Filing | Period | Filed | Where |
|---|---|---|---|
| 10-Q | 30 September 2026 | 30 October 2026 | EDGAR |
| 10-Q | 30 June 2026 | 5 August 2026 | EDGAR |
| 10-Q | 31 March 2026 | 4 May 2026 | EDGAR |
| 10-K | 31 December 2025 | 24 February 2026 | EDGAR |
| 10-Q | 30 September 2025 | 31 October 2025 | EDGAR |
| 10-Q | 30 June 2025 | 1 August 2025 | EDGAR |
| 10-Q | 31 March 2025 | 29 April 2025 | EDGAR |
| 10-K | 31 December 2024 | 25 February 2025 | EDGAR |
| 10-Q | 30 September 2024 | 29 October 2024 | EDGAR |
| 10-Q | 30 June 2024 | 2 August 2024 | EDGAR |
Reading about a stock somewhere else? Our free Chrome extension, GreekSoup Stock Ticker Lookup: Earnings, Insider Trades, 13F Holders, shows the latest quarter against a year ago, insider trades and 13F holders when you hover a $ticker such as $AAPL.